PROJECT MANAGEMENT | BUSINESS PROCESS | INVESTING | TRAVELING | VOLUNTEERING
-
The Architects: The people building InspireMD (NSPR)
Why I have room to think that InspireMD isn’t just hiring, it’s preparing for a payoff. There’s a difference between a company that has a board and a company that has been deliberately assembled with the right people for a higher-stakes phase. Most small-cap medtech companies have boards filled with capable people who bring general…
-
InspireMD (NSPR) Catalysts: Timeline For 2026
The 2026 Clock: Why InspireMD (NSPR) is a series of ticking catalysts. Investing in small-cap medtech isn’t for the faint of heart. It’s an exercise in patience punctuated by moments of sudden clarity, or sudden pain. Right now, the market is yawning. I think that’s a mistake. The patience part is watching a stock trade sideways,…
-
Why Boston Scientific (BSX) Could Be The Logical Buyer of InspireMD (NSPR)
The $1.26 Billion Gap: Why Boston Scientific (BSX) could be the elephant in the room for InspireMD (NSPR) In June 2024, Boston Scientific paid $1.26 billion for Silk Road Medical. Silk Road made a device called the ENROUTE Transcarotid Neuroprotection System, a system for performing carotid artery revascularization through a small incision in the neck,…